

## LACK OF *PRSS1* AND *SPINK1* POLYMORPHISMS IN SERBIAN ACUTE PANCREATITIS PATIENTS

Ivan Radosavljevic, Andjela Milojevic, Jelena Miljkovic, Ana Divjak, Ivana Jelic, Viktorija Artinovic, Marko Spasic,  
Bojan Stojanovic, Predrag Canovic, Slobodan Jankovic, and Natasa Djordjevic  
Faculty of Medical Sciences, University of Kragujevac, Serbia

## ODSUSTVO *PRSS1* I *SPINK1* POLIMORFIZMA KOD SRPSKIH PACIJENATA OBOLELIH OD AKUTNOG PANKREATITISA

Ivan Radosavljević, Andela Milojević, Jelena Miljković, Ana Divjak, Ivana Jelić, Viktorija Artinović, Marko Spasić,  
Bojan Stojanović, Predrag Čanović, Slobodan Janković i Nataša Đorđević  
Fakultet medicinskih nauka, Univerzitet u Kragujevcu, Srbija

Received / Priljen: 11.12.2014

Accepted / Prihvaćen: 03.03.2015.

### ABSTRACT

Acute pancreatitis represents an acute nonbacterial inflammation of the pancreas caused by a premature and ectopic activation of pancreatic digestive enzymes. Two of the most important genes in pancreatic autodigestion, *PRSS1* and *SPINK1*, were implicated in the earliest discoveries of the genetic background of pancreatitis. However, the distribution of their variations displays interethnic variability, which could significantly affect the magnitude of their proposed effects on this disease worldwide. The aim of the present study was to investigate the distribution of the most important functional variations of *PRSS1* (86A>T and 365G>A) and *SPINK1* (101A>G), and their influence on the clinical course of acute pancreatitis in Serbian patients. The study enrolled 81 subjects, the severity of disease course was determined using the Atlanta Classification system, and the genotyping was conducted using a PCR-RFLP method. *PRSS1* 86A>T and 365G>A SNPs were not observed in the study population, while *SPINK1* 101A>G was present with the frequency of 0.62% (95% CI: 0.00, 3.83%). Due to extremely low frequencies or absences of examined variations, the proposed effect of these SNPs on the severity of acute pancreatitis could not be confirmed. The results do not support routine genotyping of either *PRSS1* or *SPINK1* in Serbs.

**Keywords:** *PRSS1*, *SPINK1*, genetic polymorphism, acute pancreatitis, Serbian

### SAŽETAK

Akutni pankreatitis predstavlja akutno neinfektivno zapaljenje pankreasa, prouzrokovano prevremenom i ektopičnom aktivacijom pankreasnih digestivnih enzima. Enzimi *PRSS1* and *SPINK1*, koji igraju neke od najvažnijih uloga u pankreasnoj autodigestiji, prvi su otkriveni faktori genetske predispozicije za nastanak pankreatitisa. Ipak, zastupljenost njihovih genetskih varijacija varira u zavisnosti od etničke pripadnosti, što u velikoj mjeri utiče na značaj njihovog učesća u ovoj bolesti širom sveta. Cilj ove studije bio je da ispita distribuciju najznačajnijih funkcionalnih varijacija gena *PRSS1* (86A>T i 365G>A) i *SPINK1* (101A>G), kao i njihov uticaj na kliničku sliku bolesti, kod Srba obolelih od akutnog pankreatitisa. Istraživanje je uključilo 81 ispitanika, težina bolesti određivana je uz korišćenje Atlanta klasiifikacionog sistema, a genotipizacija je sprovedena pomoću PCR-RFLP metode. *PRSS1* polimorfizmi 86A>T i 365G>A SNPs nisu detektovani u ispitivanoj populaciji, dok je učestalost *SPINK1* 101A>G varijacije iznosila 0,62% (95% IP: 0,00; 3,83%). Obzirom na ekstremno nisku učestalost ili potpuno odsustvo ispitivanih varijacija, njihov efekat na težinu i tok akutnog pankreatitisa nije mogao biti potvrđen. Rezultati istraživanja ne preporučuju rutinsku genotipizaciju *PRSS1* i *SPINK1* kod Srba.

**Ključne reči:** *PRSS1*, *SPINK1*, genetski polimorfizam, akutni pankreatitis, srpski

### ABBREVIATIONS

**PRSS1** - cationic trypsinogen (protease serine type 1);  
**SPINK1** - pancreatic secretory trypsin inhibitor (serine protease inhibitor Kazal type 1);  
**SNP** - Single nucleotide polymorphism;

**EDTA** - ethylene diamine tetracetic acid;  
**PCR** - Polymerase chain reaction;  
**PCR-RFLP** - Polymerase chain reaction-restriction fragment length polymorphism



UDK: 616.342-002-02:575.17(497.11); 575.224(497.11) / Ser J Exp Clin Res 2015; 16 (3): 201-206  
DOI: 10.1515/SJECR-2015-0026



**Corresponding author:** Associate Professor Natasa Djordjevic, MD, PhD  
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac,  
Svetozara Markovica 69, 34 000 Kragujevac, Serbia; Tel: +381 34 306 800, ext 223; E-mail: natashadj2002@yahoo.com



## INTRODUCTION

Acute pancreatitis is an acute nonbacterial inflammation of the pancreas caused by a premature and ectopic activation of pancreatic digestive enzymes (1-3). In most cases, the disease is mild and self-limiting. However, more than 25% of patients develop a severe form of acute pancreatitis. Of those, more than half die, often during the first week after admission, due to local complications, haemodynamic instability and/or multiple organ failure (2, 4-6). As the treatment outcome highly depends on both the type and timing of the management, early differentiation between mild and severe acute pancreatitis has proven to be of the utmost clinical importance (6). Ultimately, identification of biomarkers for severe disease course upon the very first admission would be extremely beneficial for improving the chance of a good response to therapy.

Genetics, and environmental factors significantly contribute to the onset, severity and outcome of acute pancreatitis (7-9). Numerous zymogens and inflammatory mediators that regulate the process are polymorphic, and their genetic variations among pancreatitis patients have often been associated with a more severe clinical course and a worse prognosis (3, 10-12). Two of the most important role players in pancreatic autodigestion, cationic trypsinogen (protease serine type 1, *PRSS1*) and pancreatic secretory trypsin inhibitor (PSTI, serine protease inhibitor Kazal type 1, *SPINK1*), were implicated in the earliest discoveries of the genetic background of pancreatitis (13, 14). *PRSS1* is the major isoform of trypsinogen, the most important pancreatic zymogen, which is catalysed into trypsin by enterokinase or other trypsin molecules (3, 9). The *PRSS1* coding gene is polymorphic, and the most significant variations include 365G>A and 86A>T single nucleotide polymorphisms (SNPs) that are linked to a malfunction of the normal process of trypsin inactivation by trypsin-like molecules and other inhibitors of its enzymatic activity (7-9, 15). In contrast, *SPINK1* represents the first line of defence against premature trypsinogen activation as it inhibits trypsin activity within pancreatic acinar cells (3, 7, 9, 16). *SPINK1* is also encoded by a polymorphic gene, and its most important variation 101A>G has been associated with the increased risk of acute pancreatitis, especially in the presence of other significant genetic or environmental factors (7, 9, 16).

Previous research has established that both *PRSS1* and *SPINK1* polymorphisms have the potential to modulate the clinical presentation and prognosis of pancreatitis. Moreover, the distribution of these variations differs among populations (17-22), and this interethnic variability could significantly affect the magnitude of their proposed role in pancreatitis worldwide. The aim of the present study was to investigate the distribution of the most important functional *PRSS1* and *SPINK1* variations and their influence on the clinical course of acute pancreatitis Serbian patients.

## MATERIALS AND METHODS

### Study subjects

The study enrolled 81 Serbian patients with diagnosed acute pancreatitis, who were admitted to the Intensive Care Unit of the Clinical Centre Kragujevac in Serbia, from November 2011 until February 2014. Severity of disease course was determined using the Atlanta Classification system (23). The study was conducted in accordance with the Declaration of Helsinki and its subsequent revisions, and all patients or their legal representatives gave written informed consent. The approval for conducting the study was obtained from the ethics committee at the Clinical Centre Kragujevac.

### Genotyping

Genomic DNA was isolated from EDTA blood samples using the QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany). DNA concentration was determined by a Qubit™ dsDNA HS Assay Kit on the Qubit® 2.0 Fluorometer (Invitrogen, Carlsbad, CA). All PCR reactions were performed on the Techne Genius PCR Thermal Cycler (Techne, Cambridge, UK). The PCR amplicons and restriction fragments were detected by gel electrophoresis on a 2.4% agarose gel stained with Sybr® safe DNA gel stain (Invitrogen, Carlsbad, CA).

A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping *PRSS1* variation 365G>A (rs111033565, R122H) and was previously reported by Masamune et al. (24). Briefly, the PCR reaction was performed in a 16 µl mixture of 0.2 µM dNTP Mix (Thermo Scientific, Waltham, MA), 2.5 mM MgCl<sub>2</sub>, 0.2 µl of primers 5'-TGACCCACATCCCTCTGCTG-3' and 5'-TCTC-CATTTGTCTGTCTCT-3' (Invitrogen, Carlsbad, CA), 0.5 U of DreamTaqDNA Polymerase (Thermo Scientific, Waltham, MA), and ~20 ng of DNA in 1X PCR buffer (Qiagen, Hilden, Germany). The conditions included an initial denaturation at 95 °C for 5 min; 30 cycles of denaturation at 95 °C for 1 min, annealing at 64 °C for 1 min, extension at 72 °C for 1 min; and a final extension at 72 °C for 5 min. PCR generated 615 bp long amplicons, which remained uncut by the AflIII (NEB, Hertfordshire, UK) restriction enzyme in the presence of the 365G allele. Variant allele 365A was, on the other hand, digested to 323 bp and 292 bp fragments.

*PRSS1* SNP 86A>T (rs111033566, N29I) was detected using PCR-RFLP as described by Mora et al. (25). In short, PCR was performed in a 16 µl reaction mixture, containing ~20 ng of DNA, 0.2 µM dNTP Mix (Thermo Scientific, Waltham, MA), 1.5 mM MgCl<sub>2</sub>, 0.2 µl of primers 5'-CGC-CACCCCTAACATGCTAT-3' and 5'-CTCTCCCAG-GCAGACTGGCC-3' (Invitrogen, Carlsbad, CA) and 0.5 U of DreamTaqDNA Polymerase (Thermo Scientific, Waltham, MA) in a 1X PCR buffer (Qiagen, Hilden, Germany). The PCR conditions were an initial denaturation at 95 °C for 5 min; 40 cycles of denaturation at 95



°C for 30 sec, annealing at 64 °C for 30 sec, extension at 72 °C for 30 sec; and final extension at 72 °C for 5 min. The amplification resulted in 266 bp long PCR products, which were then exposed to the restriction enzyme *Taal* (Thermo Scientific, Waltham, MA). Digestion of the wild type allele yielded three fragments of 102 bp, 79 bp and 85 bp, while variant 86T allele was cut to 181 bp and 85 bp fragments.

Genotyping for *SPINK1* 101A>G (rs17107315, N34S) was conducted using the PCR-RFLP method according to Gomez-Lira et al. (16). Briefly, a 138 bp *SPINK1* region was amplified in a total PCR mixture amount of 18 µl, including ~20 ng of DNA, 0.2 µM dNTP Mix (Thermo Scientific, Waltham, MA), 1.5 mM MgCl<sub>2</sub>, 0.2 µl of primers 5'-CAATCACAGTTATTCCTCCAG-3' and 5'-TGGTGCATCCATTAAGTGCA-3' (Invitrogen, Carlsbad, CA) and 0.5 U of DreamTaqDNA Polymerase (Thermo Scientific, Waltham, MA) in a 1X PCR buffer (Qiagen, Hilden, Germany). The reaction mixture was submitted to an initial denaturation at 95 °C for 5 min; 35 cycles of denaturation at 94 °C for 30 sec, annealing at 54 °C for 30 sec, extension at 72 °C for 1 min; and final extension at 72 °C for 5 min. PCR products underwent restriction digest by the *Bsp1286I* enzyme (Thermo Scientific, Waltham, MA), which cut only variant allele to 122 bp and 16 bp fragments, while wild type 101A remained uncut.

#### Statistical analysis

Genotype data were presented as haplotype and genotype frequencies, and the 95% confidence interval calculations were calculated according to the modified Wald method.

## RESULTS

The study population was comprised of 54 men and 27 women aged between 23 and 86 (median age 59 years). Of them, 35 and 46 were classified as mild and severe acute pancreatitis patients, respectively. Among the 81 examined Serbian acute pancreatitis patients, *PRSS1* 86A>T and 365G>A SNPs were not observed. *SPINK1* variant 101G was present in the study population with a frequency of 0.62% (95% CI: 0.00, 3.83%), as only one study subject was a heterozygous carrier. This patient was a 48-years old overweight male (BMI: 29.3 kg/m<sup>2</sup>), cigarette smoker (20 cigarettes per day) and long-term (10 years) alcohol consumer (3 alcohol drinks per day) with confirmed gallstone disease, who developed a severe form of acute necrotizing pancreatitis with pancreatic pseudocyst. This was his first attack of acute pancreatitis, and no one in his family suffered from this condition before. The patient was treated with analgesics, fluid and nutritional support and antibiotics and antisecretory drugs and was discharged from the hospital fully recovered.

## DISCUSSION

In the present study, we investigated the distribution of the important functional *PRSS1* and *SPINK1* polymorphisms among Serbian patients diagnosed with mild or severe acute pancreatitis. To our best knowledge, this is the first study in Serbs on the genetic background of acute pancreatitis. Due to extremely low frequencies or the absence of examined variations, the proposed effect on severity of disease course could not be observed.

*PRSS1* is the most abundant pancreatic precursor of trypsin, which becomes active after cleavage of a short, exposed peptide chain named trypsinogen activation peptide (26). The gene encoding *PRSS1* is located on long arm of chromosome 7 (7q35), spans approximately 3.6 kb and comprises 5 exons (27). This gene is highly polymorphic, with more than 30 genetic variations reported so far ([www.uni-leipzig.de/pancreasmutation](http://www.uni-leipzig.de/pancreasmutation)). The first described and the best studied are exonic gain-of-function G>A and A>T substitutions at positions 365 and 86, respectively (13, 28). The former leads to an arginine (R) to histidine (H) replacement at codon 122 of the trypsinogen molecule (13). Because 122R represents the initial site for trypsin autohydrolysis, R122H renders trypsin resistant to inhibition and available for excessive activation of zymogens within the pancreas (29, 30). On the other hand, 86A>T results in amino acid substitution of asparagine (N) with isoleucine (I) at codon 29 (28). This causes an alteration of the secondary structure of the protein, making 122R site inaccessible for trypsin attack, thus providing the same autolysis-preventing effect as R122H (29-31). Trypsinogen activation should take place only after leaving the pancreas, as the creation of trypsin inside acinar cells would lead to pancreatic autodigestion and inflammation (1-3, 11). Previous studies found that pancreatitis develops in approximately 80% of carriers of the 365G>A or 86A>T variation. Thus *PRSS1* is considered a causative gene in hereditary pancreatitis (8, 29, 31, 32). However, in spite of the common underlying mechanism, 365G>A and 86A>T result in a different clinical course of the disease, as patients with the N29I substitution generally have milder disease symptoms with a later age of onset (33, 34).

Hereditary pancreatitis is characterized by multiple attacks of acute pancreatic inflammation that often progresses to a chronic form (8, 29, 31, 32), confirming that all types of pancreatitis share a common pathogenetic mechanism (7, 8, 11, 32, 35, 36). Therefore, it could be expected that *PRSS1* variations contribute, at least to a certain extent, to the development and severity of sporadic pancreatitis as well. However, in cases without a strong family history, the roles of *PRSS1* 365G>A and 86A>T are less understood. In addition, there are discrepancies in observations among different populations, implying interethnic differences in *PRSS1* variation frequency (21, 25, 31, 37-45). In the present study, genotyping of Serbian acute pancreatitis patients of both mild and severe clinical course revealed no carriers of either 365G>A or





86A>T variations in the *PRSS1* gene. This corresponds well to the previous data obtained from Caucasians diagnosed with non-hereditary forms of pancreatitis (8, 17, 22, 24, 25, 32, 37, 39, 40, 43, 46), arguing against genetic testing of *PRSS1* in acute pancreatitis cases in our population (35). Most likely, environmental or other genetic risk and modifying factors are involved in pathogenesis and affect the severity of this disease in Serbs.

*SPINK1* is an acute phase protein, synthesized in the acinar cells of the pancreas together with *PRSS1*. Being a strong protease inhibitor, its main role is to prevent premature trypsinogen activation and pancreatic autodigestion by creating a covalent bond between its lysine residue at position 41 and the catalytic serine residue of trypsin (12, 31, 47-50). The *SPINK1* coding gene is localized on chromosome 5 (5q32), and it consists of 4 exons spanning a region of approximately 7.5 kb (51). There are almost 40 genetic variations of *SPINK1* identified so far ([www.uni-leipzig.de/pancreasmutation](http://www.uni-leipzig.de/pancreasmutation)), with an A to G substitution at position 101 among the first and best described in connection with pancreatitis (14, 47). This is an exonic missense variation that leads to the replacement of asparagine (N) with serine (S) at codon 34 and was discovered in a pancreatitis family without *PRSS1* mutations (47). It has been suggested that N34S renders *SPINK1* incapable of inhibiting trypsinogen by causing the conformational changes within the substrate/inhibitor binding segment of the protein (14, 31). Because control of trypsin activity largely depends on *SPINK1*, it has been speculated that 101A>G, as a loss-of-function variation, could be at least be partly responsible for inflammation of the pancreas (47). However, investigations yielded contradictory results (52). While some of the studies observed no association between this variation and the disease risk or severity (22, 47, 53, 54), others reported *SPINK1* 101A>G as either a cause (14, 24) or a cofactor (16, 17, 31, 32, 37, 39, 55) in pancreatitis development.

In the present study, only one out of 81 Serbian acute pancreatitis patients was found to be a carrier of *SPINK1* 101A>G. The observed frequency belongs to the lower end of the wide span of previously published data for sporadic idiopathic pancreatitis cases among different populations. These include Brazilian (22), Chinese (44), Japanese (24, 56), French (38, 43, 47), German (14, 57), Italian (16, 40), Romanian (58), British (53), Spanish (25), Danish (41), American (31), Polish (42), or Indian (37), presenting with 0.0%, 0.0%, 0.0-3.1%, 0.0-10.3%, 0.5-23.0%, 2.7-9.4%, 5.0%, 18.0%, 18.8%, 19.5%, 25.0%, 28.6%, and 32.5% of 101A>G carriers, respectively. This overall discrepancy could be a consequence of a different composition of patients involved in the studies, i.e., different forms and aetiologies of pancreatitis cases described (38, 59). However, regardless of the risk factors and clinical presentations, all types of pancreatitis have the same pathogenesis, showing premature and uninhibited pancreatic zymogens activation (7, 8, 11, 32, 35, 36). Therefore, it is more probable that the difference in observed frequencies demonstrates an inter-

ethnic variability in terms of *SPINK1* 101A>G distribution (42, 44), which could explain earlier conflicting findings on its role in pancreatitis initiation and severity. As for the Serbian *SPINK1* 101A>G carrier presented here, the acute attack of the disease in his case was severe. However, he displayed several known pancreatitis risk factors, including being overweight, alcoholism and gallstone disease (12, 15). Given the advanced age of the patient and the absence of earlier attacks or a heredity pattern, it could be speculated that this variation acted as a disease-modifying component by lowering the threshold for development of pancreatitis triggered by other causes, possibly increasing the severity of the clinical course of this disease. Nevertheless, our observation of an extremely low frequency of *SPINK1* 101A>G prevents any definite conclusion regarding its significance in the disease aetiology and course and does not support routine genotyping in sporadic cases of acute pancreatitis in Serbs.

In conclusion, in Serbian patients diagnosed with acute pancreatitis, *PRSS1* 86A>T and 365G>A variations were not observed, while *SPINK1* 101A>G was present with a frequency of 0.62%. The proposed effect of examined variations on pancreatitis development and severity could not be confirmed. The results do not support routine genotyping of either *PRSS1* or *SPINK1* in Serbs.

## ACKNOWLEDGEMENTS

The study was financially supported by the Faculty of Medical Sciences, University of Kragujevac, Serbia, JP 10/11, and the Ministry of Science and Technological Development, Republic of Serbia, grants No. 175007 and 175056.

## REFERENCES

1. Karakayali FY. Surgical and interventional management of complications caused by acute pancreatitis. *World J Gastroenterol* 2014; 20 (37): 13412-13423.
2. Papachristou GI, Clermont G, Sharma A, Yadav D, Whitcomb DC. Risk and markers of severe acute pancreatitis. *Gastroenterol Clin North Am* 2007; 36 (2): 277-296.
3. Hirota M, Ohmuraya M, Baba H. Genetic background of pancreatitis. *Postgrad Med J* 2006; 82 (974): 775-778.
4. Wilson PG, Manji M, Neoptolemos JP. Acute pancreatitis as a model of sepsis. *Journal of Antimicrobial Chemotherapy* 1998; 41, Suppl. A: 51-63.
5. Andersson R, Andersson B, Andersson E, Axelsson J, Eckerwall G, Tingstedt B. Acute pancreatitis--from cellular signalling to complicated clinical course. *HPB (Oxford)* 2007; 9 (6): 414-420.
6. Beger HG, Rau BM. Severe acute pancreatitis: Clinical course and management. *World J Gastroenterol* 2007; 13 (38): 5043-5051.



7. Grendell JH. Genetic factors in pancreatitis. *Curr Gastroenterol Rep* 2003; 5 (2): 105-109.
8. Rolston RK, Kant JA. Genetic testing in acute and chronic pancreatitis. *Curr Gastroenterol Rep* 2001; 3 (2): 115-120.
9. Grigorescu M, Grigorescu MD. Genetic factors in pancreatitis. *Rom J Gastroenterol* 2005; 14 (1): 53-61.
10. Masamune A. Genetics of pancreatitis: the 2014 update. *Tohoku J Exp Med* 2014; 232 (2): 69-77.
11. Whitcomb DC. Genetic risk factors for pancreatic disorders. *Gastroenterology* 2013; 144 (6): 1292-1302.
12. Whitcomb DC. Genetic aspects of pancreatitis. *Annu Rev Med* 2010; 61: 413-424.
13. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nat Genet* 1996; 14: 141-145.
14. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. *Nat Genet* 2000; 25: 213-216.
15. Khan AS, Latif SU, Eloubeidi MA. Controversies in the etiologies of acute pancreatitis. *Jop* 2010; 11 (6): 545-552.
16. Gomez-Lira M, Bonamini D, Castellani C, et al. Mutations in the SPINK1 gene in idiopathic pancreatitis Italian patients. *Eur J Hum Genet* 2003; 11 (7): 543-546.
17. Pelaez-Luna M, Robles-Diaz G, Canizales-Quinteros S, Tusie-Luna MT. PRSS1 and SPINK1 mutations in idiopathic chronic and recurrent acute pancreatitis. *World J Gastroenterol* 2014; 20 (33): 11788-11792.
18. Midha S, Khajuria R, Shastri S, Kabra M, Garg PK. Idiopathic chronic pancreatitis in India: phenotypic characterisation and strong genetic susceptibility due to SPINK1 and CFTR gene mutations. *Gut* 2010; 59: 800-807.
19. Shimosegawa T, Kume K, Masamune A. SPINK1 gene mutations and pancreatitis in Japan. *J Gastroenterol Hepatol* 2006; 21 Suppl 3: S47-S51.
20. Cavestro M, Furloni L, Fontana F, et al. Association of Spink-1 (N34S) and PRSS-1 (N29I and R122H) gene mutations and chronic pancreatitis in Italy. *Gastroenterol* 2003; 124 suppl 1: A-585.
21. Applebaum-Shapiro SE, Finch R, Pfützner RH, et al. Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. *Pancreatol* 2001; 1: 439-443.
22. Bernardino AL, Guarita DR, Mott CB, et al. CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis in Brazilian patients. *Jop* 2003; 4 (5): 169-177.
23. Bradley EL. A clinically based classification system for acute pancreatitis. *Ann Chir* 1993; 47: 527-541.
24. Masamune A, Ariga H, Kume K, et al. Genetic background is different between sentinel and recurrent acute pancreatitis. *J Gastroenterol Hepatol* 2011; 26 (6): 974-978.
25. Mora J, Comas L, Ripoll E, et al. Genetic mutations in a Spanish population with chronic pancreatitis. *Pancreatol* 2009; 9: 644-651.
26. Papachristou GI, Whitcomb D. Predictors of severity and necrosis in acute pancreatitis. *Gastroenterol Clin N Am* 2004; 33: 871-890.
27. Whitcomb D, Preston RA, Aston CE. A gene for hereditary pancreatitis maps to chromosome 7q35. *Gastroenterol* 1996; 110: 1975-1980.
28. Gorry MC, Gabbai Z, Furey W. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. *Gastroenterology* 1997; 113: 1063-1068.
29. Whitcomb D. Genetic predispositions to acute and chronic pancreatitis. *Medical Clinics of North America* 2000; 84 (3): DOI: 10.1016/S0025-7125%2805%2970238-2970238.
30. Sahin-Toth M. Biochemical models of hereditary pancreatitis. *Endocrinol Metab Clin North Am* 2006; 35 (2): 303-312, ix.
31. Pfützner RH, Barmada MM, Brunskill APJ, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. *Gastroenterology* 2000; 119: 615-623.
32. Chandak GR, Idris MM, Reddy DN, Bhaskar S, Sriram PV, Singh L. Mutations in the pancreatic secretory trypsin inhibitor gene (PSTI/SPINK1) rather than the cationic trypsinogen gene (PRSS1) are significantly associated with tropical calcific pancreatitis. *J Med Genet* 2002; 39 (5): 347-351.
33. Nishimori I, Kamakura M, Fujikawa-Adachi K, et al. Mutations in exons 2 and 3 of the cationic trypsinogen gene in Japanese families with hereditary pancreatitis. *Gut* 1999; 44 (2): 259-263.
34. O'Reilly DA, Kingsnorth AN. Hereditary pancreatitis and mutations of the cationic trypsinogen gene. *Br J Surg* 2000; 87 (6): 708-717.
35. Whitcomb DC. Value of genetic testing in the management of pancreatitis. *Gut* 2004; 53 (11): 1710-1717.
36. LaRusch J, Whitcomb DC. Genetics of pancreatitis. *Curr Opin Gastroenterol* 2011; 27 (5): 467-474.
37. Chandak GR, Idris MM, Reddy DN, et al. Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis. *Gut* 2004; 53 (5): 723-728.
38. Audrezet MP, Chen JM, Le Marechal C, et al. Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. *Eur J Hum Genet* 2002; 10 (2): 100-106.
39. Drenth JP, te Morsche R, Jansen JB. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. *Gut* 2002; 50 (5): 687-692.
40. Perri F, Piepoli A, Andriulli A. On the role of CFTR, PSSR1 and PST1/SPINK1 in idiopathic chronic pancreatitis. *Eur J Hum Genet* 2003; 11 (2): 107; author reply 108.



41. Joergensen MT, Brusgaard K, Cruger DG, Gerdes AM, de Muckadell OBS. Genetic, epidemiological, and clinical aspects of hereditary pancreatitis: a population-based cohort study in Denmark. *Am J Gastroenterol* 2010; 105: 1876-1883.
42. Gasiorowska A, Talar-Wojnarowska R, Czupryniak L, et al. The prevalence of cationic trypsinogen (PRSS1) and serine protease inhibitor, Kazal type 1 (SPINK1) gene mutations in Polish patients with alcoholic and idiopathic chronic pancreatitis. *Dig Dis Sci* 2011; 56 (3): 894-901.
43. Masson E, Chen JM, Audrezet MP, Cooper DN, Ferec C. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTRC and CFTR genes in 253 young French patients. *PLoS One* 2013; 8 (8): e73522.
44. Wang W, Sun XT, Weng XL, et al. Comprehensive screening for PRSS1, SPINK1, CFTR, CTRC and CLDN2 gene mutations in Chinese paediatric patients with idiopathic chronic pancreatitis: a cohort study. *BMJ Open* 2013; 3 (9): e003150.
45. Keim V, Bauer N, Teich N, Simon P, Lerch MM, Mossner J. Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene. *Am J Med* 2001; 111 (8): 622-626.
46. O'Reilly DA, Yang BM, Creighton JE, Demaine AG, Kingsnorth AN. Mutations of the cationic trypsinogen gene in hereditary and non-hereditary pancreatitis. *Digestion* 2001; 64: 54-60.
47. Chen JM, Mercier B, Audrezet MP, Ferec C. Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. *J Med Genet* 2000; 37 (1): 67-69.
48. Treiber M, Schlag C, Schmid RM. Genetics of pancreatitis: a guide for clinicians. *Current Gastroenterology Reports* 2008; 10: 122-127.
49. Wang GP, Xu CS. Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor. *World J Gastrointest Pathophysiol* 2010; 1 (2): 85-90.
50. Ohmuraya M, Yamamura K. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. *Exp Anim* 2011; 60 (5): 433-444.
51. Horii A, Kobayashi T, Tomita N, et al. Primary structure of human pancreatic secretory trypsin inhibitor (PSTI) gene. *Biochem. Biophys. Res. Commun* 1987; 149: 635-641.
52. Aoun E, Chang CC, Greer JB, Papachristou GI, Barmada MM, Whitcomb DC. Pathways to injury in chronic pancreatitis: decoding the role of the high-risk SPINK1 N34S haplotype using meta-analysis. *PLoS One* 2008; 3 (4): e2003.
53. Threadgold J, Greenhalf W, Ellis I, et al. The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. *Gut* 2002; 50 (5): 675-681.
54. Cavestro GM, Zuppardo RA, Bertolini S, et al. Connections between genetics and clinical data: role of MCP-1, CFTR, and SPINK-1 in the setting of acute, acute recurrent, and chronic pancreatitis. *Am J Gastroenterol* 2010; 105: 199-206.
55. Schneider A, Larusch J, Sun X, et al. Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis. *Gastroenterology* 2010; 140 (1): 162-171.
56. Hirota M, Kuwata K, Ohmuraya M, Ogawa M. From acute to chronic pancreatitis: the role of mutations in the pancreatic secretory trypsin inhibitor gene. *Jop* 2003; 4 (2): 83-88.
57. Ockenga J, Dork T, Stuhmann M. Low prevalence of SPINK1 gene mutations in adult patients with chronic idiopathic pancreatitis. *J Med Genet* 2001; 38 (4): 243-244.
58. Diaconu BL, Ciobanu L, Mocan T, et al. Investigation of the SPINK1 N34S mutation in Romanian patients with alcoholic chronic pancreatitis. A clinical analysis based on the criteria of the M-ANNHEIM classification. *J Gastrointest Liver Dis* 2009; 18 (2): 143-150.
59. Witt H. The SPINK in chronic pancreatitis: similar finds, different minds. *Gut* 2002; 50: 590-591.